Deco Medical Completes Tens of Millions RMB Series A Strategic Financing to Advance Hydrogel-Based Myocardial Repair Therapy for Heart Failure

Feb 21, 2024 10:18 CST Updated 10:18

Deke Medtech

Clinical Developer of Hydrogel Myocardial Repair Technology

Source: Heart Future; Editor: Seven Kite

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

Recently,Hangzhou Deke Medtech Co., Ltd. (hereinafter referred to as "Deke Medtech")CompletedFirst Round of Strategic Financing. The financing amount isTens of millions of RMB，Exclusively invested by Tasly Capital,Will be mainly used forAccelerate the R&D and clinical trial progress of innovative product pipelines, is expected to acceleratePromote the Application of Hydrogel Myocardial Repair Technology in the Field of Heart Failure Treatment。

Deke Medtech was registered and established in March 2017 in Binjiang District, Hangzhou, as an innovative medical device R&D enterprise incubated by Denovo Medtech.YesThe World's FirstWillHydrogel Myocardial Intervention Repair Technology Applied in Heart Failure TreatmentInnovative enterprises.

Currently, Deke Medtech hasCore Technology of Hydrogel for Heart Failure Treatment and Completion of Exploratory Research, will be launched this year in more than ten top-tier tertiary hospitals nationwide.Conduct Confirmatory Clinical Trials, providing critical supporting evidence for product launch.

# Market Overview

Heart failure is not an independent disease, but the end stage of almost all cardiac diseases. Cardiac resynchronization therapy (CRT), left ventricular assist deviceExpensive costs and low penetration rate; Heart Transplant DonorSource scarcity, making it difficult for the majority of end-stage heart failure patients to receive effective treatment. Drug therapy is currently a relatively mild standard strategy for treating heart failure, butUnable to Halt the Continuous Decline of Left Ventricular Function。

Therefore,Transcatheter Gel Implantation Restores Myocardial Function, Emerging as a New Approach to Heart Failure TreatmentHydrogel is a hydrophilic three-dimensional network structure gel formed by the chemical or physical cross-linking of hydrophilic polymer compounds. Due to its high permeability, good biocompatibility, and tunable biodegradability, hydrogels are widely used in biomedical fields such as wound dressings, drug delivery systems, and in vivo implants.

Heart failure caused by dilated cardiomyopathy and myocardial infarction is suitable for auxiliary treatment with hydrogel. According to the calculation results,The total number of heart failure patients suitable for hydrogel-assisted treatment will increase significantly in a few years.The market size is nearly 10 billion yuan.Moreover, hydrogels may also be applicable in heart failure caused by other cardiovascular diseases, thus offering a market prospect with significant room for imagination.

▲Hydrogel is suitable for treating heart failure caused by dilated cardiomyopathy (DCM)

▲Hydrogel is suitable for heart failure caused by myocardial infarction (MI).

The treatment method of injecting hydrogel into the myocardium is not unique to Deke Medtech.Foreign companies are also developing similar technologies.。

MateraCor in the United StatesMyocardial Injection of Hydrogel (TCMR). This treatment method uses interventional techniques and endocardial pathways to deliver hydrogel and other potential substances (such as stem cells) to the myocardium, thereby reducing myocardial tension, improving myocardial contractility, and enhancing myocardial oxygen uptake capacity.TCMR treatment alleviates myocardial stress, restores proper cardiac function, and improves clinical symptoms in patients with advanced heart failure.。

Currently,Only Algisyl-LVR alginate hydrogel from Lonestar Heart has obtained European CE certification.Lonestar Heart, founded in the United States in 2010, is dedicated to the research and development of drugs and medical devices for the treatment of heart failure. The Phase I and II clinical trials of its product Algisyl-LVR...Confirmed the safety and effectiveness of hydrogel implant materials, Heart Failure PatientsLeft ventricular ejection fraction (LVEF) significantly increased, and quality of life improved markedly.。

# Transcatheter Endocardial Hydrogel Implantation System

Wang Yunbing, Vice Chairman of the Chinese Society for Biomaterials and professor at Sichuan University, and Dr. Nanshan Shao's team from Deke Medtech have made breakthroughs in key technologies such as the design and preparation of specific structured alginate-based hydrogel materials, recombinant humanized collagen-based hydrogel materials, and transcatheter minimally invasive interventional hydrogel delivery systems, developing a series of...The World's FirstTranscatheter Minimally Invasive Heart Failure Treatment Injectable Hydrogel Materials and Delivery System, and DevelopmentWorld's First Clinical Implant。

▲XDROP Implantable Alginate Hydrogel Animation Effect Demonstration

Deke MedtechTranscatheter Endocardial Hydrogel Injection SystemIncludingImplantable Alginate HydrogelAndTranscatheter Endocardial Injection System.

Implantable Alginate Hydrogel: By thickening the myocardial wall, it provides mechanical support to the ventricular wall, reduces ventricular wall stress, and maintains the heart's relatively good shape, size, and mechanical properties (such as left ventricular function), ultimately slowing down or even reversing ventricular dilation and improving cardiac physiological function. Additionally, alginate hydrogel exhibits excellent biocompatibility and bio-inertness.Capable of long-term presence in the human body, maintaining therapeutic effects。

Transcatheter Endocardial Injection System: Endocardial injection system canEnsure the successful implantation of alginate hydrogel into the heart, playing a therapeutic role. It accesses via the femoral artery approach, using DSA (Digital Subtraction Angiography) and TEE (Transesophageal Echocardiography).Dual Navigation Positioning Ensures Safe and Effective Delivery of Hydrogel。

Injectable - Transcatheter Endocardial Hydrogel Implantation Technology, Improving Cardiac Function by Adjusting Myocardial Stress During MotionSystolic function. Hydrogel therapy for heart failure mainly works in two aspects,On the one hand, it provides mechanical support for the ventricular wall.The three-dimensional skeleton structure of hydrogel can increase ventricular wall thickness, reduce ventricular stress, limit contractile tension, and improve myocardial remodeling, thereby enhancing cardiac function.

On the other hand, hydrogels further exert their therapeutic and repair regeneration functions by mimicking the extracellular matrix and myocardial microenvironment. Hydrogels can simulate the extracellular matrix (ECM),With a structure and function similar to ECM, it can penetrate infarcted tissue and replace degraded inflammatory ECM components, thereby inhibiting the expansion of myocardial infarction.Inhibit myocardial fibrosis.It can be seen that hydrogels have the potential to become a new treatment option for heart failure, with promising clinical application prospects and advantages.

The transcatheter endocardial hydrogel implantation technology has completed the FIM study (n=10), exploring safety and feasibility, and the results indicateAlginate hydrogel has a good therapeutic effect on heart failure patients.Among them, the 180-day postoperative follow-up results showed that the patientsLeft Ventricular End-Diastolic Volume(LVEDV) andLeft Ventricular End-Systolic Volume（LVESV）All improved., proving that the dilation and remodeling of the left ventricle have been reversed.。

# Company Introduction

Hangzhou Deke Medtech Co., Ltd. (referred to as: "Deke MedtechFounded in 2017, incubated by DeNuox Medical,Is the world's first innovative enterprise to apply hydrogel myocardial interventional repair technology in heart failure treatment.The company now owns the core technology of hydrogel for heart failure treatment and has launched cooperation with multiple top hospitals in China.

Focusing on heart failure, a major category of cardiovascular diseases, Deke Medtech continues to deepen its expertise. Heart failure is characterized by high morbidity and high mortality rates, posing a significant threat to patients' life and health. The development of new treatment technologies for heart failure is urgently needed. Deke Medtech'sXDROP™ Transcatheter Endocardial Hydrogel Injection System, throughMinimally invasive method for injecting and implanting hydrogel into the myocardial wallInternally, it thickens the myocardial wall, providing mechanical support to the ventricular wall, ultimately slowing or even reversing ventricular dilation and improving cardiac physiological function.

The company alsoIndependently Developed Transcatheter Endocardial Injection System, which can be implanted into the myocardium through a minimally invasive approach, making the entire injection process safe and controllable.Deke Medtech's implant material technology and interventional injection system are both self-developed and have applied for international patent protection., and can be used to explore other innovative cardiovascular interventional therapies.

As of the date of publication, the company's financing history is as follows:

As of the time of writingDate, partial patent information of the company is as follows:

# Global Leading Cardiovascular Device Company

Medtronic｜J&J MedTech|Boston ScientificBoston Scientific|

Edwards Lifesciences | Abbott Abbott｜

# Cardiovascular Device Companies Listed in China

# Innovative Devices Approved in China in 2023

China Cardiovascular Innovation Device List [2023 Review]

#2023 Medical Devices Entering China's Innovation Pathway

XinCheng Medical (NyokAssist Interventional Ventricular Assist System)

Beixins Life (Cardiac Pulse Field Ablation)

Hanling Medtech (Transcatheter Aortic Valve)

# Other Unlisted/Start-up Cardiovascular Companies

‍